ERBB2 and breast carcinoma: To assess the validity of this normalization factor, we applied our model to the quantification of EGFR, HER2 and HER3 expression in LS174T (colon adenocarcinoma) and SKBr3 (breast carcinoma) samples displaying variable RNA integrity (Table 3).